Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.2852W HIGH $26.13
Volume
29.34 K
Value Traded
67.70 M
Short % Float
16.78%
Days to Cover
6.7
-2.65%Week
-10.6%1 Month
-8.68%3 Month
+19.15%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.15 B
EPS (TTM)
0.07
P/E Ratio
266.43
Ent. Value
924.88 M
Total Shares
61.22 M
Float Shares
49.74 M
Insiders
18.75%
Institutions
75.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
OMDA Catalyst Timeline
Dated clinical, regulatory and corporate events for Omada Health, Inc.
Past FDA Catalysts and PDUFA Decisions
How OMDA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Omada Health, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every OMDA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Duffy Sean P.Director, Officer (Chief Executive Officer) | Option | 12,944 395,538 held | $5.82 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OMDA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.3 % (50 %) | 17.26 M | 786.33 K |
Ownership Trends
OMDA Short Interest
Shares sold short, counted twice a month.
16.78%
Short % of Float
of tradable shares sold short
8.3M
Shares Sold Short
+12.0% vs prior count
6.7 High
Days to Cover
trading days of normal volume to buy every short share back
1.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OMDA ranks across every disease it competes in
Competitive Position is a premium feature
See how OMDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOMDA News
-OMDA
Oct 20, 2026▲ +7.1%on this news
Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress
Omada Health will present research at the World Obesity and Weight Management Congress, demonstrating that participants in its GLP-1 Care Track experienced greater weight loss and improved body composition compared to those receiving usual care. The study involved 245 adults and showed significant benefits, including increased muscle mass and reduced anxiety symptoms. The findings emphasize the value of virtual care in managing obesity.
Read more →-OMDA
Oct 13, 2026▼ -16.3%on this news
Omada Health to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 5, 2026
Omada Health will announce its third quarter 2026 financial results on November 5, 2026, after market close. A conference call to discuss these results will take place at 4:30 pm ET on the same day. Participants can access a live audio webcast and a replay will be available for 12 months.
Read more →-OMDA
Sep 10, 2026Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day
Omada Health is set to present its long-term financial targets during its inaugural Investor Day. The company anticipates a minimum annual revenue growth of 20%, with a non-GAAP gross margin target of 80% and an adjusted EBITDA margin of 30%. Omada has experienced substantial growth in membership and revenue, driven by strategic partnerships and investments in technology.
Read more →-OMDA
Sep 9, 2026Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada’s GLP-1 Program
Omada Health announced a new cost savings model for its GLP-1 program, estimating up to $11,142 in savings per member over five years. The model highlights the benefits of medication persistence and engagement, projecting significant reductions in disease onset. Findings suggest that engaged members save more and that the program effectively addresses chronic care gaps.
Read more →-OMDA
Aug 6, 2026▲ +21.1%on this news
Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition
Omada Health reported a strong second quarter for 2026, with revenue increasing by 43% to $88 million and a gross margin of 73%. The company announced a leadership transition, with Sean Duffy becoming Executive Chair and Wei-Li Shao stepping in as CEO on January 1, 2027. The total number of members grew by 45% year-over-year, reflecting the success of their integrated care platform.
Read more →-OMDA
Jul 23, 2026UPDATE - Omada Health to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 6, 2026
Omada Health will announce its second quarter 2026 financial results on August 6, 2026, after market close. A conference call to discuss the results will follow at 4:30 pm ET. The call will be accessible via a live audio webcast, with a replay available for 12 months. Omada Health focuses on delivering virtual care for chronic conditions.
Read more →-OMDA
Jul 23, 2026Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on August 6, 2026
Omada Health will announce its second quarter 2026 financial results on August 6, 2026, after market close. A conference call will follow at 4:30 pm ET to discuss the results. The call will be accessible via a live audio webcast, with a replay available for 12 months. Omada Health focuses on delivering virtual care for chronic conditions.
Read more →-OMDA
Jul 15, 2026Omada Health to Host its First Investor Day on September 10, 2026
Omada Health has announced its inaugural Investor Day scheduled for September 10, 2026, in New York City. Senior management will present the company's vision, strategy, and growth plans during this half-day event. The program will also be accessible via a live webcast, with a replay available afterward.
Read more →-OMDA
Jul 13, 2026Omada Health to Participate in Canaccord Genuity’s 46th Annual Growth Conference
Omada Health announced its participation in Canaccord Genuity's 46th Annual Growth Conference, scheduled for August 11 in Boston. Senior management will engage in a fireside chat, which will also be available via webcast. The event highlights Omada's commitment to transforming healthcare delivery for chronic conditions.
Read more →-OMDA
May 27, 2026Omada Health to Participate in Goldman Sachs Global Healthcare Conference
Omada Health announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, scheduled for June 10, 2026. Senior management will engage in a fireside chat, highlighting the company's innovative approach to chronic condition management. The event will be accessible via webcast, with a replay available afterward.
Read more →-OMDA
May 7, 2026▼ -9.6%on this news
Omada Health Joins Lilly Employer Connect, Expanding Its Access Pathways for GLP-1 Care as Patients Seek More Lifestyle Support
Omada Health has joined Eli Lilly's Employer Connect program to enhance access to GLP-1 medications. This partnership aims to provide employers with transparent cost structures and comprehensive lifestyle support for obesity management. A recent survey revealed significant care gaps among GLP-1 patients, emphasizing the need for better support in primary care settings.
Read more →-OMDA
Feb 9, 2026Omada Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 5, 2026
Omada Health has announced it will release its fourth quarter and full year 2025 financial results on March 5, 2026. A conference call will follow at 4:30 PM ET to discuss these results. The company emphasizes its mission to improve chronic care through a virtual-first model that integrates human-led teams and AI technology.
Read more →-OMDA
Jan 13, 2026Omada Health Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2025
Omada Health has reported preliminary, unaudited revenue for Q4 and fiscal year 2025, showing significant growth. The company anticipates Q4 revenue between $72 million and $74 million, marking a 50% to 54% increase compared to Q4 2024. For the full year, revenue is expected to be between $256 million and $258 million, reflecting a 51% to 52% growth. Additionally, Omada's membership has grown to approximately 886,000, a 55% increase year-over-year.
Read more →About Omada Health, Inc.
Headquarters611 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next OMDA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime